FDG-PET/CT Tumor Segmentation-Derived Indices of Metabolic Activity to Assess Response to Neoadjuvant Therapy and Progression-Free Survival in Esophageal Cancer: Correlation With Histopathology Results

Purpose:To evaluate the diagnostic and prognostic abilities of PET tumor segmentation-derived indices of metabolic activity for the assessment of response to neoadjuvant chemoradiotherapy and progression-free survival in patients with esophageal cancer. Methods:Twenty-five patients with histologically confirmed esophageal cancer were retrospectively evaluated. The patients underwent PET-CT imaging before and after completion of neoadjuvant therapy. Images were evaluated visually and quantitatively with a three-dimensional threshold-based region-growing program, which calculates SUVm, SUVa of the entire tumor, metabolic tumor length (Lm) and volume (Vm) before and after therapy (SUVm1, SUVm2, SUVa1, SUVa2, Lm1, Lm2, Vm1, and Vm2, respectively). Percentage changes in these metabolic variables before and after therapy were also calculated (%SUVm, %SUVa, %Lm, %Vm, respectively). Results:SUVm1 (P = 0.018), SUVa1 (P = 0.019), Lm1 (P = 0.016), and Vm1 (P = 0.016) correlated with T-status. Advanced stage tumors (T3 + T4) had significantly higher glucose metabolism, metabolic length, and volume. Moreover, Lm1 >47.4 mm and Vm1 >29 cm3 were the best predictors of the level of tumor invasiveness. SUVm1 >12.7 and SUVa1 >5.9 could differentiate patients with positive lymph nodes from those without at presentation. %SUVa >32.3% and the SUVa1 >5.5 proved to be reliable predictors of pathologic response. SUVa2 >3.55 and SUVm2 >4.35 were the best predictors of disease progression during follow-up, with the latter having the best prognostic value. Conclusions:This study showed that FDG-PET tumor segmentation-derived indices of metabolic activity play a definite role in the evaluation of response to neoadjuvant chemoradiotherapy and progression-free survival in patients with esophageal cancer.

[1]  Gordon C Jayson,et al.  Molecular imaging of antiangiogenic agents. , 2005, The oncologist.

[2]  H. Groen,et al.  Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Tijssen,et al.  Transthoracic Versus Transhiatal Resection for Carcinoma of the Esophagus , 2007 .

[4]  N. Altorki,et al.  Three-Field Lymph Node Dissection for Squamous Cell and Adenocarcinoma of the Esophagus , 2002, Annals of surgery.

[5]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[6]  J. van Dam.  Endosonographic evaluation of the patient with esophageal cancer. , 1997, Chest.

[7]  Matthew J. McAuliffe,et al.  Medical Image Processing, Analysis and Visualization in clinical research , 2001, Proceedings 14th IEEE Symposium on Computer-Based Medical Systems. CBMS 2001.

[8]  F. Detterbeck,et al.  Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy , 1999, Cancer.

[9]  Wolfgang A Weber,et al.  Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Wolfman,et al.  Esophageal squamous carcinoma. , 1994, Radiologic clinics of North America.

[11]  M H Loew,et al.  Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy. , 1995, Cancer research.

[12]  I. Stilidi,et al.  Subtotal esophagectomy with extended 2-field lymph node dissection for thoracic esophageal cancer. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[13]  R. Munden,et al.  Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. , 2004, The Annals of thoracic surgery.

[14]  H Kato,et al.  Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  Anne Bol,et al.  Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  L. Aaltonen,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[17]  H. Kuwano,et al.  Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma , 2002, Cancer.

[18]  C B Caldwell,et al.  Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. , 2001, International journal of radiation oncology, biology, physics.

[19]  Kyung-Han Lee,et al.  18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[21]  S. Larson,et al.  Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Alavi,et al.  Radiation-induced esophagitis on FDG PET imaging. , 2003, Clinical nuclear medicine.

[23]  L. Mortelmans,et al.  Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[25]  M. Iannettoni,et al.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Rübe,et al.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  M. Hassel,et al.  A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus , 1994, Cancer.

[30]  P. D. De Leyn,et al.  Three-Field Lymphadenectomy for Carcinoma of the Esophagus and Gastroesophageal Junction in 174 R0 Resections: Impact on Staging, Disease-Free Survival, and Outcome: A Plea for Adaptation of TNM Classification in Upper-Half Esophageal Carcinoma , 2004, Annals of surgery.

[31]  V. Chiarion Sileni,et al.  Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma , 2001, Cancer.

[32]  Kyung-Ja Cho,et al.  FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. , 2005, International journal of radiation oncology, biology, physics.

[33]  S M Larson,et al.  Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.

[34]  D. Harpole,et al.  Pathologic Nodal Status Predicts Disease-Free Survival After Neoadjuvant Chemoradiation for Gastroesophageal Junction Carcinoma , 2006, Annals of Surgical Oncology.

[35]  C. Reed,et al.  Prognostic factors for the survival of patients with esophageal carcinoma in the U.S. , 2002, Cancer.

[36]  A. Walch,et al.  Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[37]  J. Bosset,et al.  Chemotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus , 1998 .

[38]  S. Medendorp,et al.  Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer , 1999, American Journal of Gastroenterology.

[39]  T. Miller,et al.  Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[40]  J. Ajani,et al.  Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. , 2003, International journal of radiation oncology, biology, physics.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[42]  J. Ajani,et al.  2‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma , 2004, Cancer.

[43]  H. Sue-Ling,et al.  An audit of the treatment of cancer of the oesophagus. , 1994, Gut.

[44]  John L. Humm,et al.  Use of PET to monitor the response of lung cancer to radiation treatment , 2000, European Journal of Nuclear Medicine.

[45]  M. Schwaiger,et al.  Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography , 2001, Annals of surgery.

[46]  R. Stuart,et al.  Surgical therapy for squamous-cell carcinoma of the oesophagus , 1994, The Lancet.

[47]  Keigo Endo,et al.  Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. , 2002, American journal of surgery.

[48]  H. Müller-Gärtner,et al.  Early changes in fluorine-18-FDG uptake during radiotherapy. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  P. Grigsby,et al.  FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. , 2006, International journal of radiation oncology, biology, physics.

[50]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[51]  P. Devitt,et al.  Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Yano,et al.  Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus , 2005, Journal of surgical oncology.

[53]  E. Griffiths,et al.  Tumor length as a prognostic factor in esophageal malignancy: Univariate and multivariate survival analyses , 2006, Journal of surgical oncology.